Testosterone prescribing among U.S. women increased more than fourfold since 2018, but treatment remains off-label, with evidence strongest for postmenopausal low sexual desire and long-term safety unresolved.
Testosterone Prescribing for U.S. Women Has More Than Quadrupled Since 2018, but No Product Is FDA-Approved
by | Nov 22, 2026 | Uncategorized | 0 comments

Recent Comments